TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Ajanta Pharmaceuticals Ltd.

AJANTPHARM on NSE · 19 Nov 2026

NIFTY 500

3,270.30 ▼ -0.11 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance

Filings

25 filings of AJANTPHARM since January 2025.

board outcome 12, transcript 8, dividend 3, results 2

FiledTypeSubject
04 Nov 2026transcriptAjanta Pharma Limited has informed the Exchange about Transcript
AI summary

Ajanta Pharma filed a written transcript of its Q2 (Jul-Sep) FY2026-27 earnings call held on 30 October 2026 at 4:00 p.m.

The transcript has been uploaded to the company's website, with a link provided in the filing.

The filing itself contains no financial figures or management commentary; the transcript content is not included in these pages.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Oct 2026board outcome
Guidance, Results
Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
AI summary

Board approved unaudited consolidated and standalone financial results for Q2 and half year ended 30 September 2026 (board meeting held 30 October 2026, 11:30 a.m. to 12:50 p.m.).

Q2 FY2027 consolidated revenue from operations Rs 1,794 cr vs Rs 1,354 cr (up 33%); adjusted EBITDA (excluding forex loss) Rs 543 cr vs Rs 369 cr (up 47%); PAT Rs 388 cr vs Rs 260 cr (up 49%).

H1 FY2027 revenue from operations Rs 3,420 cr vs Rs 2,656 cr (up 29%); adjusted EBITDA Rs 997 cr vs Rs 745 cr (up 34%); PAT Rs 722 cr vs Rs 516 cr (up 40%); ROCE 41% and RONW 31%.

Management said the India branded generic business grew ahead of IPM per IQVIA MAT September 2026, with growth of 27% above IPM, and that US generic revenue rose 41% in Q2.

An earnings conference call was scheduled for 30 October 2026 at 16:00 hrs IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Aug 2026transcriptAjanta Pharma Limited has informed the Exchange about Transcript
AI summary

Ajanta Pharma filed the written transcript of its Q1 FY2026-27 (Apr-Jun 2026) earnings call, held on 30 July 2026 at 4.15 p.m.

The transcript has been uploaded to the company's website; the filing itself gives a link to it.

The filing contains only the cover letter, so no management commentary or financial figures are stated in these pages.

The letter is signed by Gaurang Shah, Sr. VP - Legal & Company Secretary.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jul 2026dividend
Dividend / buy-back, Results
Ajanta Pharma Limited has informed the Exchange that Board of Directors at its meeting held on July 30, 2026, declared Select Dividend of Rs. 32 per equity share.
AI summary

Board approved unaudited consolidated and standalone results for the quarter ended 30 June 2026 (Q1 FY 2027). Press release: revenue from operations Rs. 1,626 cr vs Rs. 1,303 cr (up 25%); profit after tax Rs. 334 cr vs Rs. 255 cr (up 31%); adjusted EBITDA (excluding forex loss) Rs. 454 cr vs Rs. 377 cr (up 21%).

Board approved 1st interim dividend for FY 2027 of Rs. 32 per share on Rs. 2 face value, amounting to Rs. 400 cr; record date Wednesday, 5 August 2026; payment on or after 18 August 2026.

Management stated ROCE of 37% and RONW of 28% for the quarter, and that India branded generic growth exceeded IPM growth by 36% per IQVIA MAT June 2026.

An earnings conference call was scheduled for 30 July 2026 at 16:15 hrs IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jul 2026board outcome
Dividend / buy-back, Results
Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
AI summary

Board approved unaudited consolidated and standalone financial results for the quarter ended 30 June 2026 (Q1 FY2027). Press release: revenue from operations Rs 1,626 cr vs Rs 1,303 cr (up 25%); adjusted EBITDA (excluding forex loss) Rs 454 cr vs Rs 377 cr (up 21%); profit after tax Rs 334 cr vs Rs 255 cr (up 31%).

Board approved 1st interim dividend for FY2027 of Rs 32 per share on face value Rs 2, amounting to Rs 400 cr; record date 5 August 2026, payment on or after 18 August 2026.

Management stated ROCE of 37% and RONW of 28% for the quarter, and India branded generics growth exceeded IPM growth by 36% per IQVIA MAT June 2026.

An earnings conference call is scheduled for 30 July 2026 at 16:15 hrs IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
08 May 2026transcriptAjanta Pharma Limited has informed the Exchange about Transcript
AI summary

Ajanta Pharma filed a letter to BSE and NSE on 8 May 2026 enclosing a link to the written transcript of its Q4 (Jan-Mar) FY2025-26 earnings call held on 5 May 2026 at 4.30 p.m.

The transcript has been uploaded on the company's website.

The filing itself contains no financial figures or management commentary; the transcript content is not included in the pages provided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 May 2026board outcome
Results
Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Board meeting held on 5 May 2026 approved audited consolidated and standalone financial results for the quarter and year ended 31 March 2026, with unmodified auditor opinions; filing also encloses a press release and investor presentation.

Q4 FY26 consolidated revenue from operations Rs. 1,422 cr vs Rs. 1,170 cr (up 21%); EBITDA Rs. 333 cr vs Rs. 297 cr; PAT Rs. 267 cr vs Rs. 225 cr (up 18%).

FY26 consolidated revenue from operations Rs. 5,453 cr vs Rs. 4,648 cr (up 17%); EBITDA Rs. 1,395 cr vs Rs. 1,260 cr; PAT Rs. 1,056 cr vs Rs. 920 cr (up 15%).

Management stated Q4 EBITDA included a mark-to-market forex loss of Rs. 42 cr; excluding it, EBITDA was Rs. 375 cr (26% growth). FY26 ROCE was 33% and RONW 25%.

The 47th Annual General Meeting date will be informed later; an earnings conference call was scheduled for 5 May 2026 at 16:30 IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Feb 2026transcriptAjanta Pharma Limited has informed the Exchange about Transcript
AI summary

Ajanta Pharma filed a cover letter under Regulation 30 of the SEBI LODR Regulations, 2015, attaching the link to the written transcript of its Q3 (Oct-Dec) FY2025-26 earnings call.

The earnings call was held on 30 January 2026 at 4:30 p.m.

The transcript has been uploaded on the company's website; the filing itself does not contain the call content or any financial figures.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2026board outcome
Results
Ajanta Pharma Limited has informed the Exchange regarding Board meeting held on January 30, 2026.
AI summary

Board approved unaudited consolidated and standalone financial results for the quarter and nine months ended 31 December 2025, with limited review reports from B S R & Co. LLP (unmodified opinion).

Q3 FY2026 consolidated revenue from operations Rs. 1,375 cr vs Rs. 1,146 cr (up 20%); EBITDA Rs. 382 cr vs Rs. 321 cr (up 19%); PAT Rs. 274 cr vs Rs. 233 cr (up 18%).

9M FY2026 revenue from operations Rs. 4,031 cr vs Rs. 3,478 cr (up 16%); EBITDA Rs. 1,061 cr vs Rs. 962 cr (up 10%); PAT Rs. 789 cr vs Rs. 695 cr (up 14%).

Management stated the 9M EBITDA included a mark-to-market forex loss of Rs. 61 cr; excluding it, EBITDA was Rs. 1,123 cr (15% growth), and ROCE was 34% and RONW 26%.

Management said India branded generics grew 28% above IPM per IQVIA MAT December 2025, and R&D expense for 9M was Rs. 182 cr.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2026board outcome
Results
Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Ajanta Pharma filed the outcome of its board meeting held 30 January 2026, approving unaudited consolidated and standalone financial results for the quarter and nine months ended 31 December 2025.

Q3 FY2026 consolidated revenue from operations was Rs. 1,375 cr (up 20% from Rs. 1,146 cr); EBITDA Rs. 382 cr (up 19%, 28% margin); PAT Rs. 274 cr (up 18% from Rs. 233 cr).

9M FY2026 consolidated revenue from operations was Rs. 4,031 cr (up 16%); EBITDA Rs. 1,061 cr (up 10%), or Rs. 1,123 cr excluding a Rs. 61 cr mark-to-market forex loss; PAT Rs. 789 cr (up 14%).

Management said the company posted an excellent performance, with ROCE of 34% and RONW of 26% for the nine months, and that India branded generics outgrew IPM by 28% per IQVIA MAT December 2025.

An earnings conference call was scheduled for 30 January 2026 at 16:30 hrs IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2025transcriptAjanta Pharma Limited has informed the Exchange about Transcript
AI summary

Ajanta Pharma filed a letter to BSE and NSE dated 6 November 2025 stating that the written transcript of its Q2 FY2025-26 (Jul-Sep 2025) earnings call, held on 3 November 2025 at 3:00 p.m., has been uploaded to the company website.

The filing itself contains only the transcript link and no financial figures or management commentary.

The letter is signed by Gaurang Shah, Sr. VP – Legal & Company Secretary, under Regulation 30 of the SEBI LODR Regulations 2015.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Nov 2025board outcome
Dividend / buy-back, Results
Ajanta Pharma Limited has informed the Exchange regarding Board meeting held on November 03, 2025.
AI summary

Board outcome filed 3 November 2025: unaudited consolidated and standalone results for Q2 and H1 ended 30 September 2025 approved, with limited review reports from BSR & Co. LLP.

Consolidated Q2 FY2026 revenue from operations Rs. 1,354 cr (vs Rs. 1,187 cr), up 14%; EBITDA Rs. 328 cr (vs Rs. 311 cr); PAT Rs. 260 cr (vs Rs. 216 cr), up 20%. Mark-to-market forex loss of Rs. 41 cr in Q2.

H1 FY2026 revenue from operations Rs. 2,656 cr (vs Rs. 2,332 cr), up 14%; EBITDA Rs. 679 cr (vs Rs. 642 cr); PAT Rs. 516 cr (vs Rs. 462 cr), up 12%.

Board approved 1st interim dividend of Rs. 28 per share (face value Rs. 2), amounting to Rs. 349.82 cr; record date 10 November 2025; payment on or after 20 November 2025.

Management said India branded generics grew 14% in H1 and outperformed IPM growth by 32% per IQVIA MAT September 2025; an earnings call is scheduled for 3 November 2025 at 1500 hrs IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Nov 2025dividend
Dividend / buy-back, Results
Ajanta Pharma Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2025, declared Interim Dividend of Rs. 28 per equity share.
AI summary

Board approved unaudited consolidated and standalone results for Q2 and H1 FY2026 (half year ended 30 September 2025); consolidated Q2 revenue from operations Rs 1,354 cr (up 14%) and PAT Rs 260 cr (up 20%); H1 revenue Rs 2,656 cr (up 14%) and PAT Rs 516 cr (up 12%).

Board approved 1st interim dividend for FY2026 of Rs 28 per share on Rs 2 face value, amounting to Rs 349.82 cr; record date Monday, 10 November 2025; payment on or after 20 November 2025.

Management stated Q2 EBITDA of Rs 328 cr included a mark-to-market forex loss of Rs 41 cr; excluding this, EBITDA was Rs 369 cr (9% growth) with a 27% margin.

Management reported India branded generics growth of 32% above IPM per IQVIA MAT September 2025, and ROCE of 30% and RONW of 25% for H1.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Nov 2025dividend
Dividend / buy-back, Results
Ajanta Pharma Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2025, declared Interim Dividend of 28 per equity share.
AI summary

Board approved unaudited consolidated and standalone results for Q2 and H1 FY2026 (half year ended 30 September 2025); Q2 consolidated revenue from operations Rs 1,354 cr (up 14%) and PAT Rs 260 cr (up 20%); H1 revenue Rs 2,656 cr (up 14%) and PAT Rs 516 cr (up 12%).

Board approved 1st interim dividend for FY2026 of Rs 28 per share (face value Rs 2), amounting to Rs 349.82 cr; record date Monday 10 November 2025; payment on or after 20 November 2025.

Press release states management's view that the company reported an "excellent performance"; it cites a mark-to-market forex loss of Rs 41 cr in Q2 and Rs 66 cr in H1, and says excluding it Q2 EBITDA grew 9% and H1 EBITDA grew 13%.

Earnings conference call scheduled for 3 November 2025 at 1500 hrs IST; transcript to be available on the company website.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Nov 2025board outcome
Dividend / buy-back, Results
Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Board outcome for Q2 and H1 FY2026 (quarter and half year ended 30 September 2025): consolidated revenue from operations Rs 1,354 cr in Q2 (vs Rs 1,187 cr) and Rs 2,656 cr in H1 (vs Rs 2,332 cr); Q2 PAT Rs 260 cr (vs Rs 216 cr), up 20%.

Board approved 1st interim dividend of Rs 28 per share on Rs 2 face value, amounting to Rs 349.82 cr; record date Monday 10 November 2025; payment on or after 20 November 2025.

Management said the company reported an excellent performance; Q2 EBITDA of Rs 328 cr included a mark-to-market forex loss of Rs 41 cr, and excluding this EBITDA was Rs 369 cr.

Management said India branded generic growth exceeded IPM by 32% per IQVIA MAT September 2025, and US generic segment sales rose 48% in Q2 to Rs 344 cr.

An earnings conference call was scheduled for 3 November 2025 at 1500 hrs IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jul 2025transcriptAjanta Pharma Limited has informed the Exchange about Transcript
AI summary

Ajanta Pharma filed a written transcript of its Q1 FY2025-26 (April-June 2025) earnings call held on 28 July 2025 at 4.00 p.m.

The transcript has been uploaded on the company's website rather than included in the filing.

The filing is a covering letter signed by Gaurang Shah, Sr. VP - Legal & Company Secretary, addressed to BSE and NSE.

The pages provided do not include the management remarks or financial figures discussed on the call.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 Jul 2025board outcome
Results
Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Ajanta Pharma's board approved unaudited consolidated and standalone financial results for the quarter ended 30 June 2025 (Q1 FY2026), along with a press release and investor presentation.

Consolidated revenue from operations rose 14% to Rs 1,303 cr from Rs 1,145 cr a year earlier.

EBITDA was Rs 351 cr against Rs 330 cr (up 6%), with a 27% margin; PAT was Rs 255 cr against Rs 246 cr (up 4%).

Management said the mark-to-market forex loss was Rs 25 cr; excluding it, EBITDA grew 14% to Rs 376 cr at a 29% margin.

Cash flow from operations was Rs 282 cr and free cash flow Rs 209 cr; ROCE 33% and RONW 26%.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 Jul 2025board outcome
Results
Ajanta Pharma Limited has informed the Exchange regarding Board meeting held on July 28, 2025.
AI summary

Ajanta Pharma's board, at a meeting held on 28 July 2025, approved and took on record unaudited financial results for the quarter ended 30 June 2025 (Q1 FY2026).

Consolidated revenue from operations was Rs 1,303 cr against Rs 1,145 cr a year earlier, up 14%; EBITDA was Rs 351 cr against Rs 330 cr, up 6%; profit after tax was Rs 255 cr against Rs 246 cr, up 4%.

The company said EBITDA excluding a mark-to-market forex loss of Rs 25 cr was Rs 376 cr, up 14%, with a 29% margin.

Free cashflow was Rs 209 cr and cashflow from operations was Rs 282 cr, per the press release.

Management described the quarter as an "excellent performance"; an earnings conference call was scheduled for 28 July 2025 at 1600 hrs IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 May 2025transcriptAjanta Pharma Limited has informed the Exchange about Transcript
AI summary

Ajanta Pharma Limited filed the written transcript of its earnings call held on 30 April 2025 at 4.30 p.m. for Q4 (Jan-Mar) 2024-25.

The transcript has been uploaded on the company's website; the filing itself gives the link but does not reproduce the call content.

The filing is a cover letter to BSE and NSE, signed by Gaurang Shah, Sr. VP – Legal & Company Secretary.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Apr 2025board outcome
Dividend / buy-back, Results
PFA Audited (Consolidated & Standalone) Financial Results for the Quarter and Year Ended 31st March 2025 pursuant to Regulation 33 of SEBI (LODR).
AI summary

Ajanta Pharma filed the outcome of its board meeting held on 30 April 2025, which approved audited consolidated and standalone financial results for the quarter and year ended 31 March 2025.

Q4 FY2025 consolidated revenue from operations was Rs. 1,170 cr (up 11% from Rs. 1,054 cr); EBITDA Rs. 297 cr (up 7%); PAT Rs. 225 cr (up 11%).

FY2025 consolidated revenue from operations was Rs. 4,648 cr (up 10% from Rs. 4,209 cr); EBITDA Rs. 1,260 cr (up 7%); PAT Rs. 920 cr (up 13%).

During FY2025 the company distributed Rs. 700 cr to shareholders (Rs. 349 cr as dividend and Rs. 351 cr as buyback), a 76% payout of FY2025 PAT.

The company will host an earnings conference call on 30 April 2025 at 1630 hrs IST; the date of the 46th AGM will be informed later.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Apr 2025board outcome
Dividend / buy-back, Results
Ajanta Pharma Limited has informed the Exchange regarding Board meeting held on April 30, 2025.
AI summary

Ajanta Pharma filed the outcome of its board meeting held on 30 April 2025, which approved the audited consolidated and standalone financial results for the quarter and year ended 31 March 2025.

Q4 FY25 consolidated revenue from operations was Rs. 1,170 cr (up 11% from Rs. 1,054 cr); EBITDA Rs. 297 cr (up 7% from Rs. 278 cr); PAT Rs. 225 cr (up 11% from Rs. 203 cr).

FY25 consolidated revenue from operations was Rs. 4,648 cr (up 10% from Rs. 4,209 cr); EBITDA Rs. 1,260 cr (up 7%); PAT Rs. 920 cr (up 13% from Rs. 816 cr).

During FY25 the company distributed Rs. 700 cr to shareholders (Rs. 349 cr dividend and Rs. 351 cr buyback), equal to 76% of FY25 PAT.

The company will announce the date of its 46th Annual General Meeting later, and an earnings conference call was scheduled for 30 April 2025 at 1630 hrs IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Feb 2025results
Results
PFA Integrated Filing- Financials for the quarter ended 31st December 2024
AI summary

Ajanta Pharma filed unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024, approved by the Board on 30 January 2025.

Q3 FY25 consolidated revenue from operations was Rs 1,146.13 crore, against Rs 1,105.15 crore in the quarter ended 31 December 2023.

Q3 FY25 net profit was Rs 232.88 crore, against Rs 210.03 crore a year earlier; basic EPS was Rs 18.60 (face value Rs 2).

Nine-month revenue from operations was Rs 3,477.69 crore, against Rs 3,154.63 crore, and nine-month net profit was Rs 695.13 crore, against Rs 613.45 crore.

The statutory auditors (B S R & Co. LLP) issued an unmodified limited review opinion.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Feb 2025transcriptAjanta Pharma Limited has informed the Exchange about Transcript
AI summary

Ajanta Pharma Limited filed the written transcript of its Q3 FY25 earnings call held on 30 January 2025 at 4.30 p.m., under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015.

The transcript has been uploaded to the company's website and is accessible via a link provided in the filing.

The filing itself contains no financial figures, outlook or other management commentary in the pages provided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2025board outcome
Results
Ajanta Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on January 30, 2025.
AI summary

Ajanta Pharma's board approved unaudited consolidated and standalone financial results for the quarter and nine months ended 31 December 2024, with the board meeting running from 1.30 p.m. to 3.20 p.m. on 30 January 2025.

Q3 FY2025 consolidated revenue from operations was Rs. 1,146 cr (vs Rs. 1,105 cr), up 4%; EBITDA Rs. 321 cr (vs Rs. 314 cr), up 2%; PAT Rs. 233 cr (vs Rs. 210 cr), up 11%.

9M FY2025 consolidated revenue from operations was Rs. 3,478 cr (vs Rs. 3,155 cr), up 10%; EBITDA Rs. 962 cr (vs Rs. 894 cr), up 8%; PAT Rs. 695 cr (vs Rs. 613 cr), up 13%.

9M FY2025 free cash flow was Rs. 675 cr, with ROCE of 35% and RONW of 26%, as stated in the press release.

Management described the performance as excellent; the India branded generic business grew 12% in Q3 and the Africa institution business fell 61% in Q3.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2025results
Results
Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
AI summary

Ajanta Pharma reported unaudited consolidated results for the quarter and nine months ended 31 December 2024 after its board meeting on 30 January 2025.

Q3 FY2025 revenue from operations was Rs 1,146 cr (vs Rs 1,105 cr), up 4%; EBITDA Rs 321 cr (vs Rs 314 cr), up 2%; PAT Rs 233 cr (vs Rs 210 cr), up 11%.

9M FY2025 revenue from operations was Rs 3,478 cr (vs Rs 3,155 cr), up 10%; EBITDA Rs 962 cr (vs Rs 894 cr), up 8%; PAT Rs 695 cr (vs Rs 613 cr), up 13%.

9M FY2025 cash flow from operations was Rs 985 cr and free cash flow was Rs 675 cr; ROCE 35% and RONW 26%.

Management described the performance as excellent; India branded generics Q3 sales rose 12% to Rs 345 cr, and US generics Q3 sales rose 4% to Rs 263 cr. Africa Institution Q3 sales fell 61% to Rs 33 cr.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in